Items Tagged ‘hormone-receptor positive’

October 26th, 2016

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

By

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

View full entry

Tags: 2016, Breast Cancer, ESMO, Femera, hormone-receptor positive, HR+ metastatic, letrozole, Metastatic Breast Cancer, MONALEESA-2 clinical, News, ribociclib LEE011


October 9th, 2015

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

View full entry

Tags: abemaciclib, Breast Cancer, CDK, hormone-receptor positive, HR+, metastatic, Metastatic Breast Cancer, MONARCH 3, News, Recurrent Breast Cancer


June 3rd, 2015

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer

By

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER)-negative metastatic breast cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England […]

View full entry

Tags: Breast Cancer, ER-positive, Faslodex, HER2-negative, hormone-receptor positive, Ibrance, Metastatic Breast Cancer, News


March 5th, 2015

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer

By

The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and progesterone receptor (PR) who have previously failed treatment with an aromatase inhibitor. Each year roughly 200,000 U.S. women are […]

View full entry

Tags: Breast Cancer, Faslodex, fulvestrant, hormone-receptor positive, Metastatic Breast Cancer, News, pictilisib, Recurrent Breast Cancer